Desai D D; Krishnan M R; Swindle J T; Marion T N ΑU y of Tennessee, Department of Mig piology and Immunology, Univers CS Memphis 38163.. AI 26833 (NIAID) NC BRSG-RR05423 (NCRR) AI 07238 (NIAID) JOURNAL OF IMMUNOLOGY, (1993 Aug 1) 151 (3) 1614-26. SO Journal code: IFB. ISSN: 0022-1767. CY United States Journal; Article; (JOURNAL ARTICLE) DTLA English Abridged Index Medicus Journals; Priority Journals; Cancer Journals FS EM Spontaneous anti-DNA antibodies in autoimmune mice have the AB characteristics of antibody produced by Ag-specific, clonally selective B cell stimulation. The nature of the somatically derived antibody V region structures recurrent among spontaneous anti-DNA antibodies suggests that DNA or DNA-protein complexes may provide the antigenic stimulus for autoimmune anti-DNA antibody. In order to test this hypothesis directly, we have immunized normal, nonautoimmune-predisposed mice with complexes formed with DNA and an immunogenic, DNA-binding peptide. The highly immunogenic peptide, Fusl, forms an internal domain of a 128-amino acid ubiquitin-fusion protein from Trypanosoma cruzi. DNA-Fusl complexes formed with native calf thymus DNA induced anti-DNA antibody in normal, nonautoimmune-predisposed mice that is similar in isotype and specificity to spontaneous anti-DNA antibody in (NZB x NZW)F1 autoimmune mice. The progressive nature of the development of dsDNA specificity in the immunized mice was also analogous to what is observed in the spontaneous anti-DNA antibody response of autoimmune (NZB $\dot{ exttt{X}}$ NZW)F1 mice. DNA-Fus1 immunized mice that produced IgG that bound to dsDNA had low to moderate levels of proteinuria and glomerular deposits of IgG. This experimental immunization system may be useful for understanding the immunologic basis for autoimmunity to DNA.

=> d his

L2

(FILE 'HOME' ENTERED AT 12:56:37 ON 11 AUG 2000)

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:01:10 ON 11 AUG 2000

L1 19243 S UBIQUITIN

2065 S L1 AND (CHIMER? OR FUSION# OR HYBRID#)

L3 232205 S L2 AND VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE

L4 48 S L2 AND (VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE OR ADJUVAN

L5 26 DUP REM L4 (22 DUPLICATES REMOVED)

L6 214 S UBIQUITIN FUSION PROTEIN?

L7 4 S L6 AND VACCINE

L8 131 S L2 AND (VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE OR ADJUVAN

L9 65 DUP REM L8 (66 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 13:15:10 ON 11 AUG 2000

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:20:42 ON 11 AUG 2000

FILE 'STNGUIDE' ENTERED AT 13:20:44 ON 11 AUG 2000

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:21:45 ON 11 AUG 2000

FILE 'STNGUIDE' ENTERED AT 13:21:46 ON 11 AUG 2000

Ubiquition

epitope or vaccinett or immunoseme or antigentity

ummune response or adjustant or antigentity

ubiquition the fusion or chimer? or hybrid?)

13 + N-termintett

(3+(stimulat? or elicit?)

file hits - dgere genbank, biotecrabs uspatfull, wounder